Saintsun Pharma

Saintsun Pharma is a clinical-stage biopharmaceutical company based in China, specializing in the discovery and development of innovative biologics and small molecule drugs for oncology and other serious diseases. The company leverages its proprietary antibody-drug conjugate (ADC) and multi-specific antibody platforms to create a diverse pipeline of candidates targeting well-validated and novel pathways such as CD47 and Claudin 18.2. Saintsun Pharma operates integrated R&D centers and manufacturing facilities to support its transition from drug discovery to commercialization. Its lead programs are currently undergoing clinical evaluation in both China and international markets, focusing on high-unmet-need indications like gastric and pancreatic cancers.